851885-42-2

Basic information

• Product Name: Benzoic acid, 3-[(1S)-2-methoxy-1-methylethoxy]-5-(phenylmethoxy)-, methyl ester
• CAS NO: 851885-42-2
• Molecular Formula: C19H22O5
• Molecular Weight: 330.381
• Mol File: 851885-42-2.mol
• Article Data: 17

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 3-[(1S)-2-methoxy-1-methylethoxy]-5-(phenylmethoxy)-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 3-[(1S)-2-methoxy-1-methylethoxy]-5-(phenylmethoxy)-, methyl ester(851885-42-2)
• EPA Substance Registry System: Benzoic acid, 3-[(1S)-2-methoxy-1-methylethoxy]-5-(phenylmethoxy)-, methyl ester(851885-42-2)

Safety Data

• Hazardous Substances Data: 851885-42-2(Hazardous Substances Data)

Upstream product

• 4984-22-9 (R)-1-methoxy-2-propanol 
• 54915-31-0 methyl 3-(benzyloxy)-5-hydroxybenzoate 
• 26550-55-0 (S)-1-Methoxy-propan-2-ol 
• 2446-83-5 di-isopropyl azodicarboxylate 
• 100-39-0 benzyl bromide 
• 2150-44-9 1-carbomethoxy-3,5-dihydroxybenzene 

Downstream Products

• 851885-41-1 3-{[(1S)-1-methyl-2-(methyloxy)ethyl]oxy}-5-[(phenylmethyl)oxy]benzoic acid 
• 1325708-43-7 3-(6-cyclopropanesulfonylpyridin-3-yloxy)-5-((S)-2-methoxy-1-methylethoxy)benzoic acid methyl ester 
• 1325708-46-0 3-(6-cyclopropanesulfonylpyridin-3-yloxy)-5-((S)-2-methoxy-1-methylethoxy)benzoic acid 
• 915949-14-3 N-(2-aminopyridin-3-yl)-3-(benzyloxy)-5-[(1S)-2-methoxy-1-methylethoxy]benzamide 
• 915948-91-3 (S)-3-{[2-(azetidin-1-ylcarbonyl)pyrimidin-5-yl]oxy}-5-[(1S)-2-methoxy-1-methylethoxy]benzoic acid 
• 915949-01-8 methyl 3-[5-(dimethylcarbamoyl)pyrazin-2-yl]oxy-5-[(2S)-1-methoxypropan-2-yl]oxy-benzoate 
• 915948-83-3 3-(3H-imidazo[4,5-b]pyridin-2-yl)-5-[(1S)-2-methoxy-1-methylethoxy]phenol 
• 1093121-03-9 C₂₈H₂₈FN₃O₅S 
• 915948-88-8 3-((S)-2-methoxy-1-methyl-ethoxy)-5-((S)-1-methyl-2-phenyl-ethoxy)-benzoic acid methyl ester 
• 915948-89-9 3-((S)-2-methoxy-1-methyl-ethoxy)-5-((S)-1-methyl-2-phenyl-ethoxy)-benzoic acid 
• 915771-82-3 3-hydroxy-5-{[(1S)-2-hydroxy-1-methylethyl]oxy}-N-(3-methyl-1,2,4-thiadiazol-5-yl)benzamide 
• 915771-40-3 3-hydroxy-5-{[(1S)-1-methyl-2-(methyloxy)ethyl]oxy}benzoic acid 
• 863504-90-9 3-{(1S)-2-methoxy-(1-methylethyl)oxy}-5-{phenylmethyloxy}-N-(3-methyl-1,2,4-thiadiazol-2-yl)benzamide 
• 863504-89-6 3-hydroxy-5-{(1S)-2-methoxy-(1-methylethyl)oxy}-N-(3-methyl-1,2,4-thiadiazol-2-yl)benzamide 

Relevant articles and documents

Decoration of an α-Resorcylate Nucleus as Part of the Manufacture of a Glucokinase Activator

The need to define a set of processes for the manufacture of a glucokinase activator called for an evaluation of different strategies to differentiate the hydroxyls of an α-resorcylic acid derivative. While direct functionalization proved possible, it did not allow access to crystalline intermediates that offered control over the rejection of process impurities. The strategy taken forward involved the installation of a benzoyl protecting group using careful control of pH in order to achieve useful levels of selectivity. This allowed the remaining α-resorcylate hydroxyl to be functionalized using a Mitsunobu reaction, with liquid-liquid partitioning being used to separate downstream intermediates of interest away from the redox byproducts of this reaction. Downstream challenges that were overcome in order to deliver a commercially viable means of manufacturing the API included developing an amidation reaction with a poorly reactive aminopyrazine coupling partner.

BENZAMIDE COMPOUNDS AS GLUCOKINASE ACTIVATORS AND THEIR PHARMACEUTICAL APPLICATION

Benzamide compounds of formula (I), their stereoisomers, tautomers, prodrugs, pharmaceutically acceptable salts, polymorphs, solvates and formulations thereof useful as Glucokinase activators or modulators are disclosed. The disclosure further relates to

NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME

Compounds are provided which are phosphonate and phosphinate activators and thus are useful in treating diabetes and related diseases and have the structure wherein is a heteroaryl ring; R4 is —(CH2)n-Z-(CH2)m—PO(OR7)(OR8), —(CH2)nZ-(CH2)m—PO(OR7)Rg, —(CH2)n-Z-(CH2)m—OPO(OR7)Rg, —(CH2)nZ—(CH2)m—OPO(R9)(R10), or —(CH2)nZ—(CH2)m—PO(R9)(R10);R5 and R6 are independently selected from H, alkyl and halogen;Y is R7(CH2)s or is absent; andX, n, Z, m, R4, R5, R6, R7, and s are as defined herein; or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.